Profit before interest, taxes and amortization: herontx.com (HRTX)

Graphic logo of Heron Therapeutics, Inc. (HRTX)

Amidst the expansion of Heron Therapeutics (HRTX) into the US hospital sector, the operating profit summary demonstrates cash flow volatility, with the indicator standing at 0.00. Revenue stability is supported by the integration of analgesics into surgical protocols. The company has now shifted its focus from development to sales optimization and achieving full business break-even.

Heron Therapeutics (HRTX) - Operating profit EBITDA from 11/23/2025 to 11/15/2026

Summary analytical data breakdowns for Heron Therapeutics Inc (HRTX)

- company stock exchange capitalization indicators:
Analysis of all company metrics:Heron Therapeutics
Manufactured product of Heron

For Heron Therapeutics (HRTX), whose revenues depend on FDA approvals and the implementation of analgesics, operating cash flow reflects the actual efficiency of drug commercialization. By analyzing the company's aggregate EBITDA, an investor assesses the business's daily ability to convert sales into cash, given that prolonged peaks in this indicator may signal an imminent market cycle reversal and a decline in asset value.

Who Heron Therapeutics competes with

Income before deduction of interest, taxes and amortization INCY|HCM - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Nuvation Bio Inc|Day One (DAWN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MNPR|INBX (inhibrx.com) - Operating profit EBITDA|Operating profit before deduction of amortization i-mabbiopharma.com (IMAB)|Profit before payment of interest, taxes and amortization Fennec (FENC)|NVCT - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Coherus BioSciences, Inc CHRS|Corbus Pharmaceuticals, Inc. - Profit before payment of interest, taxes and amortization|CRDF - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization BeyondSpring Inc.|BCAB: Operating profit EBITDA|Operating profit before depreciation charges Lixte Biotechnology Holdings LIXT|Operating profit before deduction of amortization CTXR|Profit before interest, taxes and amortization Cellectar Biosciences CLRB|Operating profit before deduction of amortization BLRX (BioLineRx Ltd.)|CANF (Can-Fite BioPharma Ltd.) - Income before deduction of interest, taxes and amortization|Aprea Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization KZIA (Kazia)|Silexion Therapeutics - Operating profit EBITDA|Income before deduction of interest, taxes and amortization NCNA (nucana.com)|CMRX: Operating profit EBITDA|Profit before interest, taxes and amortization cyclacel.com (CYCC)|Profit before payment of interest, taxes and amortization g1therapeutics.com|KRON: Income before deduction of interest, taxes and amortization|Operating profit EBITDA KTRA|Operating profit EBITDA Oncternal Corp (ONCT)|Profit before payment of interest, taxes and amortization Portage PRTG